Gilead and Jounce's JTX-1811 Receives US FDA's IND Clearance for Cancer Immunotherapies
Shots:
- Jounce to receive $85M upfront and $35M in its common stock under the terms of Sep 2020 agreement. Additionally- it is eligible to receive upto $660M in future clinical- regulatory and commercial milestone payments along with royalties based upon the w/w sales after receiving a $25M milestone
- Jounce led the development of JTX-1811 through IND clearance- and thereafter Gilead has exclusive rights to develop and commercialize the program
- JTX-1811 is a mAb- targeting CCR8 and selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells
| Ref: Globe Newswire | Image: Gilead
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com